Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53
HOS-116510 · Präparat HOS-094447
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal product Interaction Recommendations concerning examples by therapeutic Geometric mean change (%) co-administration area HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir dolutegravir AUC ↓ 22% PREZISTA co-administered with dolutegravir C24h ↓ 38% low dose ritonavir and dolutegravir dolutegravir Cmax ↓ 11% can be used without dose darunavir ↔* adjustment. * Using cross-study comparisons to historical pharmacokinetic data Raltegravir Some clinical studies suggest raltegravir At present the effect of raltegravir may cause a modest decrease in on darunavir plasma darunavir plasma concentrations. concentrations does not appear to be clinically relevant. PREZISTA co-administered with low dose ritonavir and raltegravir can be used without dose adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dolutegravir (HOS-089992) raltegravir (HOS-086187) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 3624439a772037e61fff0a5eea8efaa03adf8eb80018ddfa2836aa9a83b31b4d · Zeichen 4730–6351 im Abschnitt